When people say ketamine these days, they're talking about the mixture of the R and the S molecules. The alternative idea is to develop a treatment that blocks the NMDA receptor more potently. And logic goes something like, then we can give less total dose. That'll be safer in terms of side effects or better in terms of tolerability. It's not clear to me which strategy will be followed.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode